IQVIA Holdings Inc.

This is our first report on an IQVIA Holdings, an international player providing services to the clinical research and health information technology sectors. The company delivered an all-around beat and bookings were around $10.8 billion. IQVIA expanded access to clinical research. In partnership with Tasso, they have launched the first self-collection safety lab panel for clinical trial participants in the United States, enhancing their decentralized clinical trial capabilities. Their DCT program obtained GDPR approval in Europe. Also, their linked devices company added 50 new clients, including contracts with two of the top 10 pharmaceutical firms. The company expanded its digital marketing capabilities by acquiring Lasso Marketing. Furthermore, the demand for their commercial services had a positive growth trend even if they are experiencing short-term swings in discretionary spending categories, such as consulting. IQVIA also continues to see strong double-digit year-over-year growth in bookings in oncology. The management anticipates good operating performance in 2023, with 9% to 11% organic revenue growth. We initiate coverage on the stock of IQVIA Holdings Inc. with a ‘Buy’ rating.